Orchestra Biomed Holdings Stock Alpha and Beta Analysis
| OBIO Stock | 5.63 0.15 2.60% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Orchestra BioMed Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Orchestra BioMed over a specified time horizon. Remember, high Orchestra BioMed's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Orchestra BioMed's market risk premium analysis include:
Beta 2.2 | Alpha (0.29) | Risk 4.93 | Sharpe Ratio (0.01) | Expected Return (0.05) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Orchestra |
Orchestra BioMed Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Orchestra BioMed market risk premium is the additional return an investor will receive from holding Orchestra BioMed long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Orchestra BioMed. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Orchestra BioMed's performance over market.| α | -0.29 | β | 2.20 |
Orchestra BioMed expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Orchestra BioMed's Buy-and-hold return. Our buy-and-hold chart shows how Orchestra BioMed performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Orchestra BioMed Market Price Analysis
Market price analysis indicators help investors to evaluate how Orchestra BioMed stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Orchestra BioMed shares will generate the highest return on investment. By understating and applying Orchestra BioMed stock market price indicators, traders can identify Orchestra BioMed position entry and exit signals to maximize returns.
Orchestra BioMed Return and Market Media
The median price of Orchestra BioMed for the period between Sat, Aug 31, 2024 and Fri, Nov 29, 2024 is 5.57 with a coefficient of variation of 9.52. The daily time series for the period is distributed with a sample standard deviation of 0.53, arithmetic mean of 5.53, and mean deviation of 0.44. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 6819 shares by Darren Sherman of Orchestra BioMed at 5.65 subject to Rule 16b-3 | 09/06/2024 |
2 | Disposition of 1800 shares by Fain Eric S of Orchestra BioMed at 5.43 subject to Rule 16b-3 | 09/09/2024 |
3 | Disposition of 1800 shares by Fain Eric S of Orchestra BioMed at 5.34 subject to Rule 16b-3 | 09/10/2024 |
4 | Acquisition by David Hochman of 2500 shares of Orchestra BioMed at 4.91 subject to Rule 16b-3 | 09/24/2024 |
5 | Acquisition by David Hochman of 2000 shares of Orchestra BioMed at 4.73 subject to Rule 16b-3 | 09/25/2024 |
6 | OBIO and CATTI Collaborate to Boost Canadas Biomanufacturing Capacity for Advanced Therapies | 11/04/2024 |
7 | Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update | 11/12/2024 |
8 | Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference | 11/26/2024 |
About Orchestra BioMed Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Orchestra or other stocks. Alpha measures the amount that position in Orchestra BioMed Holdings has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.0981 | 0.0811 | 0.0641 | 0.0894 | Days Of Inventory On Hand | 124.72 | 312.86 | 286.51 | 179.55 |
Orchestra BioMed Upcoming Company Events
As portrayed in its financial statements, the presentation of Orchestra BioMed's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Orchestra BioMed's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Orchestra BioMed's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Orchestra BioMed. Please utilize our Beneish M Score to check the likelihood of Orchestra BioMed's management manipulating its earnings.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Orchestra BioMed
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Orchestra BioMed Backtesting, Orchestra BioMed Valuation, Orchestra BioMed Correlation, Orchestra BioMed Hype Analysis, Orchestra BioMed Volatility, Orchestra BioMed History and analyze Orchestra BioMed Performance. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Orchestra BioMed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.